| $385M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $91M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
Over the last 12 months, insiders at Coherus Oncology, Inc. have bought $0 and sold $0 worth of Coherus Oncology, Inc. stock.
On average, over the past 5 years, insiders at Coherus Oncology, Inc. have bought $49,668 and sold $2.61M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,700 shares for transaction amount of $49,668 was made by Stilwell McDavid (Chief Financial Officer) on 2021‑06‑09.
| 2025-05-23 | Sale | Wahlstrom Mats | director | 99,988 0.0843% | $0.74 | $73,881 | +101.36% | |
| 2023-11-22 | Sale | Lanfear Dennis M | President & CEO | 223,100 0.2098% | $2.02 | $449,770 | -6.44% | |
| 2021-10-15 | Sale | Stilwell McDavid | Chief Financial Officer | 3,507 0.0045% | $16.80 | $58,919 | -30.65% | |
| 2021-09-29 | Sale | HEALY JAMES | director | 286,076 0.3546% | $16.12 | $4.61M | -26.09% | |
| 2021-09-28 | Sale | HEALY JAMES | director | 48,329 0.0622% | $17.17 | $829,809 | -27.59% | |
| 2021-09-27 | Sale | HEALY JAMES | director | 100,150 0.1287% | $18.06 | $1.81M | -30.86% | |
| 2021-06-09 | Stilwell McDavid | Chief Financial Officer | 3,700 0.0049% | $13.42 | $49,668 | +0.96% | ||
| 2021-06-08 | Sale | Lanfear Dennis M | President & CEO | 31,054 0.0411% | $13.56 | $421,229 | +0.59% | |
| 2021-03-09 | Sale | Vexler Vladimir | Chief Scientific Officer | 114,240 0.1583% | $16.25 | $1.86M | -9.44% | |
| 2021-03-05 | Sale | Anicetti Vincent R | Chief Operating Officer | 26,649 0.0357% | $15.46 | $412,065 | -7.55% | |
| 2021-02-17 | Sale | Anicetti Vincent R | Chief Operating Officer | 2,488 0.0034% | $17.45 | $43,418 | -13.71% | |
| 2021-02-01 | Sale | Viret Jean-Frederic | Chief Financial Officer | 7,402 0.0124% | $21.55 | $159,513 | -13.35% | |
| 2021-01-25 | Sale | Viret Jean-Frederic | Chief Financial Officer | 46,144 0.0647% | $19.95 | $920,736 | -21.18% | |
| 2021-01-19 | Sale | Anicetti Vincent R | Chief Operating Officer | 2,500 0.0034% | $17.94 | $44,852 | -13.26% | |
| 2020-12-17 | Sale | Anicetti Vincent R | Chief Operating Officer | 2,500 0.0034% | $17.51 | $43,780 | -10.94% | |
| 2020-12-10 | Sale | Vexler Vladimir | Chief Scientific Officer | 17,626 0.0246% | $18.05 | $318,066 | -11.68% | |
| 2020-12-09 | Sale | Vexler Vladimir | Chief Scientific Officer | 49,512 0.0685% | $18.24 | $903,084 | -13.28% | |
| 2020-12-07 | Sale | Anicetti Vincent R | Chief Operating Officer | 8,791 0.0122% | $18.42 | $161,896 | -13.80% | |
| 2020-12-04 | Sale | Anicetti Vincent R | Chief Operating Officer | 49,000 0.0675% | $18.85 | $923,694 | -16.42% | |
| 2020-12-03 | Sale | Anicetti Vincent R | Chief Operating Officer | 49,756 0.0692% | $18.67 | $929,079 | -14.87% |
| LILLY ELI & CO | 3042019 2.4851% | $4.32M | 1 | 0 | +82.59% | |
| Lanfear Dennis M | President & CEO | 731693 0.5977% | $1.04M | 0 | 10 | |
| FMR LLC | 361594 0.2954% | $513,463.48 | 0 | 3 | ||
| Troendle August J. | director | 268428 0.2193% | $381,167.76 | 0 | 3 | |
| Richards Christos | director | 63836 0.0521% | $90,647.12 | 0 | 2 | |
| Viret Jean-Frederic | Chief Financial Officer | 61295 0.0501% | $87,038.90 | 0 | 24 | |
| Anicetti Vincent R | Chief Operating Officer | 53402 0.0436% | $75,830.84 | 0 | 25 | |
| Vexler Vladimir | Chief Scientific Officer | 53386 0.0436% | $75,808.12 | 0 | 3 | |
| Herman Alan C. | Chief Scientific Officer | 49651 0.0406% | $70,504.42 | 0 | 26 | |
| FINCK BARBARA K | Chief Medical Officer | 37043 0.0303% | $52,601.06 | 0 | 5 | |
| Stilwell McDavid | Chief Financial Officer | 31611 0.0258% | $44,887.62 | 1 | 1 | +0.96% |
| HEALY JAMES | director | 0 0% | $0 | 1 | 8 | +82.59% |
| Szela Mary T | director | 0 0% | $0 | 0 | 1 | |
| Wahlstrom Mats | director | 0 0% | $0 | 0 | 8 | |
| Watler Peter K. | Chief Technical Officer | 0 0% | $0 | 0 | 7 |
$22,693,451 | 105 | 8.15% | $158.06M | |
$6,979,075 | 22 | -28.22% | $155.9M | |
$16,153,236 | 20 | -28.79% | $172.18M | |
$20,234,041 | 17 | 2.09% | $192.64M | |
$448,999,793 | 15 | -19.99% | $171.71M | |
$245,302 | 15 | -4.08% | $157.11M | |
$4,701,608 | 14 | -4.34% | $157.92M | |
$1,037,470 | 13 | 78.00% | $202.37M | |
$19,167,169 | 10 | 28.48% | $186.14M | |
$344,394 | 8 | -22.26% | $182.49M | |
$119,804,612 | 8 | -17.22% | $186.82M | |
$22,090,972 | 7 | -3.49% | $158.65M | |
$36,049,976 | 5 | -3.82% | $154.71M | |
$164,999,952 | 5 | -44.44% | $168.07M | |
$32,007,657 | 4 | -45.65% | $183.53M | |
$32,289,200 | 3 | -5.46% | $182.08M | |
Coherus BioSciences, Inc. (CHRS) | $16,003,671 | 3 | 55.38% | $173.82M |
$12,498 | 2 | 39.61% | $181.26M | |
$86,200 | 1 | -19.57% | $186.67M |
| Increased Positions | 64 | +53.33% | 5M | +9.6% |
| Decreased Positions | 44 | -36.67% | 5M | -10.24% |
| New Positions | 26 | New | 2M | New |
| Sold Out Positions | 10 | Sold Out | 1M | Sold Out |
| Total Postitions | 140 | +16.67% | 51M | -0.64% |
| Blackrock, Inc. | $14,330.00 | 8.65% | 10.46M | -279,724 | -2.6% | 2025-09-30 |
| Vanguard Group Inc | $14,140.00 | 8.53% | 10.32M | -249,408 | -2.36% | 2025-09-30 |
| Tang Capital Management Llc | $6,983.00 | 4.21% | 5.1M | 0 | 0% | 2025-09-30 |
| Kohlberg Kravis Roberts & Co. L.P. | $4,159.00 | 2.51% | 3.04M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $3,755.00 | 2.27% | 2.74M | +64,750 | +2.42% | 2025-09-30 |
| State Street Corp | $3,046.00 | 1.84% | 2.22M | +4,843 | +0.22% | 2025-09-30 |
| Cm Management, Llc | $2,877.00 | 1.74% | 2.1M | -150,000 | -6.67% | 2025-09-30 |
| C Worldwide Group Holding A/S | $2,642.00 | 1.59% | 1.93M | 0 | 0% | 2025-09-30 |
| Panagora Asset Management Inc | $1,885.00 | 1.14% | 1.38M | +581,639 | +73.22% | 2025-09-30 |
| Charles Schwab Investment Management Inc | $1,361.00 | 0.82% | 993,092 | +11,720 | +1.19% | 2025-09-30 |